Virus injection plus immunotherapy for advanced colorectal, stomach, or liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether a special virus injected directly into tumors can help your body fight cancer when combined with an immunotherapy drug. It is for people with advanced colorectal, stomach, or liver cancer that has spread and who have tumors that can be reached for injection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal, gastric, or liver cancer that has spread, and you have at least one tumor (1 cm or larger) that can be directly injected with the study drug.
- You have not had radiation, ablation, or surgery on the target tumor recently — or if you have, it's been at least 4 weeks and that tumor has grown.
- You have completed any previous cancer treatments at least 4 weeks ago (or 5 drug half-lives, whichever is longer) and have recovered from any side effects.
- Your heart, lungs, liver, and kidneys are working well enough to safely receive the injection.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a standard tumor-removal procedure (ablation) with an investigational drug injected into the liver to see if it helps your immune system fight the cancer. It is for people whose colorectal cancer has spread only to the liver and who are having all visible liver tumors treated with ablation.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
This study tests a new approach that combines a modified virus (H101) injected directly into the tumor with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced breast cancer who have already tried standard treatments and could not continue chemotherapy.
This trial tests combining a special virus injected directly into the tumor with two approved drugs (tislelizumab and lenvatinib) for advanced liver cancer that hasn't been treated before. The goal is to see if this triple approach can shrink tumors and improve outcomes.
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.